Nortriptyline

From Wikipedia, the free encyclopedia

(Redirected from Pamelor)
Jump to: navigation, search
Nortriptyline
Systematic (IUPAC) name
3-(10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5-ylidene)- N-methyl-1-propanamine
Identifiers
CAS number 72-69-5
894-71-3 (hydrochloride)
ATC code N06AA10
PubChem 4543
DrugBank APRD00602
Chemical data
Formula C19H21N 
Mol. mass 263.377 g/mol
Pharmacokinetic data
Bioavailability well absorbed
Metabolism Hepatic
Half life 16 and 90 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

C

Legal status

Prescription only

Routes oral

Nortriptyline is a second generation tricyclic antidepressant marketed as the hydrochloride under the trade names Aventyl®, Pamelor® and Nortrilen®. It is used in the treatment of depression and childhood nocturnal enuresis (bedwetting). In addition it is sometimes used for chronic pain modification, Migraine, and labile affect in some neurological conditions.

Contents

Nortriptyline inhibits the reuptake of serotonin, and, to a lesser extent, norepinephrine (noradrenalin) (Basic & Clinical Pharmacology, 10th Edition, Bertram G. Katzung, MD, PhD). Operant conditioning techniques in rats and pigeons suggest that nortriptyline has a combination of stimulant and depressant properties.

Nortriptyline is FDA-approved for the treatment of depressive disorders. In the United Kingdom it may also be used for treating nocturnal enuresis with courses of treatment lasting no more than three months. It is also used off-label for the treatment of panic disorder, irritable bowel syndrome, prevention of migraine headaches and chronic pain or neuralgia modification (particularly Temporomandibular joint disorder).[1] It can also aid in quitting smoking with one study showing a six-month abstinence rate of 14% for subjects receiving nortriptyline compared to 3% for subjects not undergoing pharmacological treatment.[2] Research has been done suggesting it can reduce symptoms of ADHD.[citation needed]

Nortriptyline is metabolised in the liver by hepatic enzyme CYP2D6. Approximately 7 to 10 percent of Caucasians are poor metabolisers and might experience more adverse effects, so a lower dosage is often necessary in these individuals.[citation needed] Blood levels of nortriptyline should be obtained during long term treatment to avoid toxicity and optimise response.

For depression: low starting doses are used, increasing as necessary to 75–100mg (0–50mg for adolescents and the elderly). Maximum daily dosage is 150mg.[3]

For the management of noctiral enuresis: lower dosages are used with the maximum period of treatment, including gradual withdrawal, being three months and a full examination including electrocardiogram (ECG or EKG) required before further courses.[3]

For its off-label use for migraine and headache prophylaxis and treating chronic pain: treatment is started at very low 10mg once at night to minimise side-effects. The dose is then increased every two weeks if required to a maximum of 150mg.

Dry mouth, drowsiness, orthostatic hypotension, urinary retention, constipation, and rapid or irregular heartbeat. Some sexual side effects may be a problem as well. Less commonly, seizures and ECG/EKG changes have been reported, especially in overdose.

Alcohol may exacerbate some of its side effects and should be avoided.

However, the incidence of side effects with nortriptyline is somewhat lower than with the first generation tricyclics (e.g. imipramine (Tofranil®), amitriptyline (Elavil®)).

Closer monitoring is required for those with a history of cardiovascular disease, stroke, glaucoma and/or seizures as well as those who have hyperthyroidism or are receiving thyroid medication.

In the acute recovery phase after myocardial infarction (e.g. heart attack). As for all tricyclic antidepressants concurrent use, or failure to allow a two week gap, with monoamine oxidase inhibitors (MAO inhibitors, e.g. phenelzine, tranylcypromine, etc.) may precipitate hyperpyretic crises and/or severe convulsions; fatalities have occurred.

The symptoms and the treatment of an overdose are largely the same as for the other tricyclic antidepressants.

  1. ^ (2002) in Sweetman SC: Martindale. The complete drug reference, 33, Pharmaceutical Press. ISBN 0-85369-499-0. 
  2. ^ Prochazka A, Weaver M, Keller R, Fryer G, Licari P, Lofaso D (1998). "A randomized trial of nortriptyline for smoking cessation.". Arch Intern Med 158 (18): 2035-9. PMID 9778204. 
  3. ^ a b British National Formulary 45 March 2003

Advanced Search
Included Web Search Engines


Safe Search

close

Top Matching Results

Occasionally Search.com will highlight specialized results that are based on the context of your query. Examples of specialized results include specific links to news, images, or video.

Top Matching Results may highlight information from other Search.com pages, content from the CNET Network of sites, or third party content. The listings are based purely on relevance. Search.com does not receive payment for listings in this section but our partners that provide this data may get paid for listing these products.

Sponsored Links

This section contains paid listings which have been purchased by companies that want to have their sites appear for specific search terms and related content. These listings are administered, sorted and maintained by a third party and are not endorsed by Search.com.

Search Results

Search.com sends your search query to several search engines at one time and integrates the results into one list which has been sorted by relevance using Search.com's proprietary algorithm. You can customize the list of search engines included in your metasearch from the preferences.

The search engines that are used in your metasearch may allow companies to pay to have their Web sites included within the results. To view the Paid Inclusion policy for a specific search engine, please visit their Web site. Search.com does not accept payment or share revenue with any search engine partner for listings in this section.